Trichostatin A Modulates Thiazolidinedione-Mediated Suppression of Tumor Necrosis Factor α-Induced Lipolysis in 3T3-L1 Adipocytes

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Lu, Juu Chin ^a   Chang, Yu Tzu ^a   Wang, Chih Tien ^b   Lin, Yu Chun ^a   Lin, Chun Ken ^a   Wu, Zhong Sheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RETINOIC ACID; THYROID HORMONE RECEPTOR; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; LIPOLYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; TISSUE DIFFERENTIATION;

EID: 84881228022     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071517     Document Type: Article

References (55)

1. Olefsky JM, Glass CK, (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219-246.
2. Glass CK, Olefsky JM, (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15: 635-645.
3. Ryden M, Arner P, (2007) Tumour necrosis factor-alpha in human adipose tissue - from signalling mechanisms to clinical implications. J Intern Med 262: 431-438.
4. Ruan H, Lodish HF, (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14: 447-455.
5. Chen X, Xun K, Chen L, Wang Y, (2009) TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct 27: 407-416.
6. Green A, Rumberger JM, Stuart CA, Ruhoff MS, (2004) Stimulation of lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. Diabetes 53: 74-81.
7. Zhang HH, Halbleib M, Ahmad F, Manganiello VC, Greenberg AS, (2002) Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 51: 2929-2935.
8. Souza SC, Yamamoto MT, Franciosa MD, Lien P, Greenberg AS, (1998) BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 47: 691-695.
9. Yang X, Zhang X, Heckmann BL, Lu X, Liu J, (2011) Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to TNF-{alpha}-induced lipolysis in adipocytes. J Biol Chem 286: 40477-40485.
10. Ryden M, Dicker A, van Harmelen V, Hauner H, Brunnberg M, et al. (2002) Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem 277: 1085-1091.
11. Ryden M, Arvidsson E, Blomqvist L, Perbeck L, Dicker A, et al. (2004) Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 318: 168-175.
12. Souza SC, Palmer HJ, Kang YH, Yamamoto MT, Muliro KV, et al. (2003) TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes. J Cell Biochem 89: 1077-1086.
13. Lee MJ, Fried SK, (2012) Glucocorticoids antagonize tumor necrosis factor-alpha-stimulated lipolysis and resistance to the antilipolytic effect of insulin in human adipocytes. Am J Physiol Endocrinol Metab 303: E1126-1133.
14. Rahn Landstrom T, Mei J, Karlsson M, Manganiello V, Degerman E, (2000) Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem J 346 Pt 2: 337-343.
15. Rosenbaum SE, Greenberg AS, (1998) The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes. Mol Endocrinol 12: 1150-1160.
16. Ricote M, Glass CK, (2007) PPARs and molecular mechanisms of transrepression. Biochim Biophys Acta 1771: 926-935.
17. Xu WS, Parmigiani RB, Marks PA, (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
18. Reichert N, Choukrallah MA, Matthias P, (2012) Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci 69: 2173-2187.
19. Marks PA, Breslow R, (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
20. Blaheta RA, Cinatl J Jr, (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511.
21. Hamed S, (2007) Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res 75: 1-9.
22. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, et al. (2009) Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23: 388-401.
23. Jallon P, Picard F, (2001) Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 24: 969-978.
24. Lagace DC, Nachtigal MW, (2004) Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 279: 18851-18860.
25. Kim SN, Choi HY, Kim YK, (2009) Regulation of adipocyte differentiation by histone deacetylase inhibitors. Arch Pharm Res 32: 535-541.
26. Catalioto RM, Maggi CA, Giuliani S, (2009) Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program. Exp Cell Res 315: 3267-3280.
27. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, et al. (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3: 903-910.
28. Wiper-Bergeron N, Salem HA, Tomlinson JJ, Wu D, Hache RJ, (2007) Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. Proc Natl Acad Sci U S A 104: 2703-2708.
29. Huang J, Imamura T, Babendure JL, Lu JC, Olefsky JM, (2005) Disruption of microtubules ablates the specificity of insulin signaling to GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem 280: 42300-42306.
30. Kershaw EE, Schupp M, Guan HP, Gardner NP, Lazar MA, et al. (2007) PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am J Physiol Endocrinol Metab 293: E1736-1745.
31. Liao W, Nguyen MT, Yoshizaki T, Favelyukis S, Patsouris D, et al. (2007) Suppression of PPAR{gamma} Attenuates Insulin-Stimulated Glucose Uptake by Affecting Both GLUT1 and GLUT4 in 3T3-L1 Adipocytes. Am J Physiol Endocrinol Metab 293: E219-227.
32. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
33. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA, (2005) Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev 19: 453-461.
34. Lu JC, Piazza TM, Schuler LA, (2005) Proteasomes mediate prolactin-induced receptor down-regulation and fragment generation in breast cancer cells. J Biol Chem 280: 33909-33916.
35. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, et al. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437: 759-763.
36. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, et al. (2007) Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 25: 57-70.
37. Qiao L, Schaack J, Shao J, (2006) Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147: 865-874.
38. Lagace DC, McLeod RS, Nachtigal MW, (2004) Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 145: 5493-5503.
39. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, et al. (2007) PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 3: e64.
40. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, et al. (1997) Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin. J Biol Chem 272: 20230-20235.
41. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, et al. (1996) Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 97: 2553-2561.
42. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS, (2002) PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16: 27-32.
43. Deng J, Liu S, Zou L, Xu C, Bin G, et al. (2012) Lipolysis response to endoplasmic reticulum stress in adipose cells. J Biol Chem 287: 6240-6249.
44. Rapold RA, Wueest S, Knoepfel A, Schoenle EJ, Konrad D, (2013) Fas activates lipolysis in a Ca2+-CaMKII-dependent manner in 3T3-L1 adipocytes. J Lipid Res 54: 63-70.
45. Yang Y, Yang G, (2010) Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes. Biochem Cell Biol 88: 853-860.
46. Zu L, He J, Jiang H, Xu C, Pu S, et al. (2009) Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. J Biol Chem 284: 5915-5926.
47. Zu L, Jiang H, He J, Xu C, Pu S, et al. (2008) Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes. Mol Pharmacol 73: 215-223.
48. Ren T, He J, Jiang H, Zu L, Pu S, et al. (2006) Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J Mol Endocrinol 37: 175-183.
49. Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, et al. (2010) Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 59: 61-70.
50. Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, Maassen JA, (2004) Mitogen-activated protein kinase (MAPK) phosphatase-1 and-4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 18: 1697-1707.
51. Ito A, Suganami T, Miyamoto Y, Yoshimasa Y, Takeya M, et al. (2007) Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem 282: 25445-25452.
52. Hinds TD Jr, Stechschulte LA, Cash HA, Whisler D, Banerjee A, et al. (2011) Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma (PPARgamma). J Biol Chem 286: 42911-42922.
53. Chen CS, Weng SC, Tseng PH, Lin HP, Chen CS, (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280: 38879-38887.
54. Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, et al. (1999) Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19: 6286-6296.
55. Khan O, La Thangue NB, (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94.